Skip to Content

'
Ala Abudayyeh, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1468
Houston, TX 77030
Room Number: FCT13.6101
Phone: 713-745-9331
Fax: 713-792-8743
Email: aabudayyeh@mdanderson.org

Education & Training

Degree-Granting Education

2003 University of Texas-Houston Medical School, Houston, TX, MD, Internal Medicine
1999 Baylor University, Waco, TX, BS, Magna Cum Laude, Biology

Postgraduate Training

6/2009-8/2011 Nephrology Fellowship, Nephrology, Baylor College of Medicine, Houston, TX
6/2004-6/2006 Resident, Internal Medicine, Baylor College of Medicine, Houston, TX
8/2003-6/2006 Internal Medicine Resident, Baylor College of Medicine, Houston, TX

Board Certifications

2011 American Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Hedrick E, Lee S, Kim G, Abdelrahim M, Jin U, Abudayyeh A, Safe S. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. Urologic Oncology: Seminars and Original Investigations. In Press.
2. Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, Safe S. Mechanism of Metformin-dependent Inhibition of mTOR and Ras Activity in Pancreatic Cancer: Role of Sp Transcription Factors. J Biol Chem 289(40):27692-701, 10/3/2014. e-Pub 8/20/2014. PMCID: PMC4183806.
3. Abudayyeh AA, Lahoti A, Salahudeen AK. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 85(5):1002-4, 5/2014. PMID: 24786870.
4. Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 30(3):853-61, 6/2012. e-Pub 1/4/2011. PMID: 21197621.
5. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 29(1):41-51, 2/2011. e-Pub 10/2009. PMID: 19851711.
6. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD, Smith R, Safe S. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 125(8):1965-74, 10/2009. PMCID: PMC2766353.
7. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30(7):1193-201, 7/2009. e-Pub 4/2009. PMCID: PMC2704282.
8. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 8(5), May 2009. e-Pub 5/2009.
9. Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A. Safe S. 5,5'-Dibromo-bis(e'-indolyl) methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Mol Cancer Ther. 8(3):533-42, 3/2009.
10. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533-42, 3/2009. e-Pub 3/2009. PMID: 19258429.
11. Abdelrahim, M., Safe, S., Baker, C., Abudayyeh, A. RNAi and Cancer: implications and application. J RNAi Gene Silencing 2(1):136-45, 2/2006.

Grant & Contract Support

Title: BK virus as an indicator of poor immune recovery and chronic kidney disease in Hematopoietic Stem cell transplants A prospective study
Funding Source: ASN Foundation
Role: Principal Investigator
Duration: 7/1/2015 - 6/30/2017

Last updated: 1/7/2015